Venetoclax is the first-in-class selective Bcl-2 inhibitor (Bcl-2-specific BH3 mimetic) that induces cell death in MM cells, particularly in those patients harboring t(11,14)(q13;q32). This evidence concerns the gene BCL2 and Miyoshi myopathy.